Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises BioGaia and its subsidiary Infant Bacterial Therapeutics in connection with a share distribution and separate listing
Mandate

Vinge advises BioGaia and its subsidiary Infant Bacterial Therapeutics in connection with a share distribution and separate listing

February 15, 2016

Vinge advises BioGaia AB (publ) and its subsidiary Infant Bacterial Therapeutics AB (publ) ("IBT") in connection with the proposed distribution of BioGaia’s shares in IBT to the shareholders of BioGaia. In connection with the distribution, IBT will apply for listing of the company's series B shares on Nasdaq First North. IBT is developing a drug (IBP-9414) against necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

Vinge's team consists of Erik Sjöman, Dain Hård Nevonen, Ludvig Frithiof and Joel Wahlberg. Tora Hansjons advises on tax matters.

Related

Vinge advises Stride.VC in connection with its investment in Anotherblock

 In 2022, Anotherblock launched a blockchain-based marketplace for music rights. The company has through its platform granted fans access to streaming rights from several known artists. The investment round is led by Stride.VC.
May 25, 2023

Vinge advises M42 on its acquisition of Diaverum from Bridgepoint

 Vinge is advising M42, an Abu Dhabi-based tech-enabled healthcare company in connection with is acquisition of Diaverum AB.
May 22, 2023

Vinge advises Tele2 in connection with its notes issuance and tender offer

 Vinge advises Tele2 AB (publ) in connection with its issuance of senior unsecured fixed rate notes in an amount of EUR 500 million and its parallel tender offer in respect of its previously issued notes due 2024.
May 22, 2023